This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
by Zacks Equity Research
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
BMRNNegative Net Change ATRANegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
VRTXNegative Net Change BEAMPositive Net Change NTLANegative Net Change CRSPPositive Net Change
biotechs crispr medical pharmaceuticals
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
by Zacks Equity Research
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
VYGRPositive Net Change CTMXNegative Net Change MIRMNegative Net Change CSTLPositive Net Change
biotechs
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
REGNPositive Net Change GSKPositive Net Change MRNANegative Net Change NTLANegative Net Change
biotechnology biotechs medical pharmaceuticals
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
by Zacks Equity Research
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.
BMRNNegative Net Change CTMXNegative Net Change IFRXPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACADNegative Net Change VYGRPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
by Zacks Equity Research
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
JNJPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechs medical pharmaceuticals
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
by Sundeep Ganoria
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Kymera Provides Pipeline Objectives for 2025, Stock Gains
by Zacks Equity Research
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
SNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACADNegative Net Change VYGRPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
by Zacks Equity Research
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
BMRNNegative Net Change CTMXNegative Net Change MDGLNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
by Zacks Equity Research
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
TGTXNegative Net Change VYGRPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
by Kinjel Shah
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
GSKPositive Net Change JNJPositive Net Change LLYPositive Net Change
biotechs pharmaceuticals
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
by Zacks Equity Research
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea HD (on a preliminary basis).
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
by Zacks Equity Research
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.
VYGRPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash
by Zacks Equity Research
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.
MRKPositive Net Change MRNANegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
by Zacks Equity Research
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
HALOPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
INCYPositive Net Change BMRNNegative Net Change EXELNegative Net Change HALOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
by Zacks Equity Research
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
JNJPositive Net Change SDZNYNegative Net Change
biotechs medical pharmaceuticals
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
by Zacks Equity Research
Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.
BIIBNegative Net Change PBYIPositive Net Change CSTLPositive Net Change
biotechs
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
by Zacks Equity Research
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
CTMXNegative Net Change CSTLPositive Net Change SDZNYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
by Zacks Equity Research
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
TEVAPositive Net Change FOLDNegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
by Zacks Equity Research
Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.
REGNPositive Net Change ALNYPositive Net Change RHHBYPositive Net Change PBYIPositive Net Change
biotechs
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
by Zacks Equity Research
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
BMYNegative Net Change MRKPositive Net Change EXELNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
PFENegative Net Change MRKPositive Net Change CSTLPositive Net Change ERASNegative Net Change
biotechs medical pharmaceuticals